The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Last year on 16 jan, so expected later this week or early next week.
Hopefully the second half of 2020 was improving.
They could comment on
signs of improvement for clinical studies post COVID eg 2021 order book
Has generic competition for foscavir emerged
New Managed access programmes
Erwinase take on
Proleukin revitalisation
The dirs have made 15% on their late 2020 buys, some more would boost confidence in the future further which is needed if the 800 range is to seen in 2021.
They were appointed around the time of the non bid. Dumping your Nomad after 6 months is unusual, but we don’t know whether Clin wants a cheaper option or JPM does not want to be a Nomad on Aim for Clin.
Weren't JPM only appointed in May?
A cheaper option? Or no defence required anymore?
Atleast there is an update this year
But it contained v Few numbers......give us some sales trends to work with....Please
Any half positive comments should get the shares going as they've been left behind in the wider rally..
Likely to be a trading update with the AGM on Thursday.
Hopefully a bit more upbeat...the last few have been Ambiguously cautious and spooked the market....they should have a better idea of the way forward
It looked good at the time but not to BOD.
We will not know how close an offer came to be made.....if one had been tabled the BOD would have had to consider it.
850 might be a winning number now.......or Iovance may get their act together early next year....and add 50% (this was a recent broker forecast ha ha).
The rumoured £10.50 to £11.50 bid from Advent would look good right now! https://www.thisismoney.co.uk/money/news/article-8417997/Advent-International-bought-Cobham-eyes-Clinigen.html
Conference presentations are often a good idea....and will push a rising SP along.
I doubt investec clients will want to be force fed Clin until the market starts to rerate the Share price. What will be the catalyst? Some positive news about Proleukin sales. Iovance might have done that, but is delayed....when there is progress the SP may recover strongly, until then it will probably hover around 600-700.
Clinigen management are presenting at the Investec conference today...should see some buying interest on the back of it...expect to rally into year end
At last some positive news....expanding this particular drug's indications is very welcome.
I would rather they do this Themselves than rely on others to revitalise a drug.
SP now back to results day....NEDs up 10% so far.
Can they produce more good news soon?
NEDs made a concerted buy yesterday.
Remember CEO and CFO bought at £4 earlier in the year.
CBB given your views of the Board this should be your Cue to load up on the basis they know something we don’t.
But you have to ask yourself what is fundamentally different between now and a few months ago. From their business perspective you would have to say very little.
CBB I will be sitting on my hands too and hoping there will be a bounce.
When I first bought CLIN I also bought Dechra (dph). I put about the same money into each about 1600. CLIn is now worth 1200, DPH is 3400. It was DPH that looked expensive at the time, but it has been proven better quality, the difference may also be partly down to AIM vs the Main Board.
AIM is def more volatile so I am hopeful of being able to get out of Clin with a profit (as I could have done earlier this year).
£8 anyone?
and back in my pocket goes the top up money !..... i'm not even entertaining the idea if the price is north of 540, for me, this POS is trading in the region of it's worth, it's not undervalued in any way so going to take forever to get to where i need, to get what's owed
And Octopus investments is in with a new 5% disclosable position.
A4007035.....if the answer to your questions is yes, then the SP should take care of itself (high). Clearly the market is taking a different view at the moment.....while the market can be wrong it represents a lot of competing views.....unfortunately the company is heavily dependent on others (Eg Iovance) to deliver and they have not /are delayed.
Clin made a big investment in Proleukin using debt. There is a Growing risk this does not pay off. Clin will need to show its efforts to rejuvenate the drug is working.
Try not to think of the share price.
Think about the business itself and ask yourselves
- Are they cash generative
- Have management delivered on their promises in the main
- are they growing year on year
- Do they have a strong balance sheet
If you concentrate too much on the sp you'll suffer from tunnel vision.
If the above answers are all yes and continue to be yes the business will be successful. That is what matters here.
Investors have to be long.
can't say i blame you, this is now heading back down intot he region it may be worth me averaging down in the hopes of a smaller recovery will allow me out at what I'm owed
I hope you're wrong but good timing so far and wish you all the best :)
Hi chaps, I'm out now (at a fairly big loss!), i'll look to come back in in around 6-12 months when things should start looking more interesting- gla
I bought back in (didn't post on LSE first time round but had from £5-£7 or so)...current avg 625, looks cheap vs rest of healthcare. may add bit more if it falls again (did this morning)
thank you godshare, yes a4007035 there had to be something (isnt there always) but i still come back to the simple fact this share swings too much for something that thinks it's worth double digits in £s
Looks like i'm going to be forced to average down in the simple hopes of getting out earlier.
So, expectation was that licence application would be submitted late 2020. Now anticipated 2021 but no more specific than that.
Thanks for posting that report godshare. At least it explains today’s drop.
Thanks Godshare this will delay rejuvenation of Proleukin, hence the hit. Iovance was recently touted as able to generate a 50%uplift in revenue.
Iovance seems to be in dispute about how to measure the concentration of the therapy rather than effectiveness, so I this maybe a safety concern as like a drug dose there will be a minimised recommended dose to reduce side effects. Still better to have this now rather than submit and get a complete response letter.
Hopeful this is only a delay rather than a terminal blow.